Fusion Antibodies plc
FAB.L · LSE
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 10.6% | -37.2% | 102.9% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | -£0 |
| % Margin | 22.1% | 13.9% | 26.9% | -9.4% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | -£0 | £0 | -£0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -108.6% | -129.9% | -65.8% | -146.7% |
| Other Income/Exp. Net | £0 | £0 | £0 | £0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | -£0 | £0 | -£0 | £0 |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -61.1% | -126% | -62.8% | -146.1% |
| EPS | -0.005 | -0.01 | -0.014 | -0.017 |
| % Growth | 54.5% | 27.2% | 20% | – |
| EPS Diluted | -0.005 | -0.01 | -0.014 | -0.017 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -56.8% | -117.2% | -61% | -129.9% |